SEC EDGARJUN 11 min read$ILMN

Meister Keith A. sold $361K of ILMN (indirect holdings)

Meister Keith A. sold 2,225 indirectly-held shares of ILLUMINA, INC. (ILMN) at $162.44 ($0.36M total) on 2026-05-29.

Original reporting

SEC EDGAR · Meister Keith A.

Published Jun 1, 2026, 10:04 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Bearish

low confidence

Mentioned

$ILMN

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNBearishLow

Why it matters

The market may interpret insider selling as caution, but without a linked corporate event the trading signal is typically weak.

Market read

Provides incremental sentiment data (insider reduced exposure) but no new operational or financial catalyst.

What to watch

Check whether other insiders/funds filed around the same period and whether there were concurrent news items affecting Illumina’s guidance or demand.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed June 1; sale executed May 29

Background

This is an SEC Form 4 insider transaction disclosure (director, open-market sale).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNBearishLow confidence

Context

Illumina director Keith A. Meister sold 2,225 shares in an open-market transaction disclosed via SEC Form 4 on May 29.

Expected impact

Likely small, short-lived drift or no sustained move; monitor for follow-on insider activity or concurrent fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure without accompanying guidance, contract, or operational catalyst; insider sales are often non-informational and the plan status is not clearly tied to a 10b5-1 structure.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst stated.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A single director open-market sale can be routine (tax/portfolio rebalancing) and may not reflect a change in Illumina fundamentals.

Key entities

issuer
Illumina, Inc.
Subject of the Form 4 insider transaction; director sold shares on May 29, disclosed June 1.
insider
Keith A. Meister
Director who executed the sale of 2,225 shares at $162.44/share.

Read at source ← All news

SEP 18

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

scanx.trade3 min

SEP 18

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

benzinga.com3 min

SEP 17

$ILMNMedAI 9/10

There's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higher

Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.

cnbc.com3 min

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

SEP 16

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

yahoo.com3 min

SEP 15

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv

stockstotrade.com2 min